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This prospective study assessed the impact of
18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) on the staging and
possible consequential changes of treatment regimen in patients with Hodgkin’s lymphoma (HL). A total of 88 consecutive patients
with histologically verified Hodgkin’s lymphoma underwent a PET scan in addition to conventional staging procedures. Treatment was
based on the conventional staging only, and the results of the FDG-PET did not affect the treatment strategy. The evaluation focused
on the suggested change in clinical stage according to the Ann Arbor classification and on the suggested change in treatment strategy
rather than on a lesion-by-lesion analysis. Using all the methods performed as the standard of reference,
18F-FDG-PET staging was
concordant with conventional staging in 70 out of 88 patients (80%).
18F-fluorodeoxyglucose positron emission tomography
suggested a change to a different clinical stage in 18 patients (20%). Management would have been changed in 16 patients (18%):
intensification of treatment in nine patients (10%) and minimisation of treatment in seven patients (8%). In the 44 patients with early
disease (stage IA–IIB), treatment would have been intensified in nine out of 44 patients (20%).
18F-fluorodeoxyglucose positron
emission tomography is a relevant noninvasive method that supplements conventional staging procedures and should therefore be
used routinely to stage Hodgkin’s lymphoma, particularly in patients with an early stage.
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Today, Hodgkin’s lymphoma (HL) is one of the malignant diseases
with the highest rate of cure in adults based on improved
chemotherapy and radiotherapy. The most important objective of
staging is the exact detection of all nodal and extranodal lymphoma
manifestations present to be able to administer the optimal therapy
according to the stage and to the risk situation. The criteria for
detecting involvement are mainly based on the assessment of the
size of the lymph nodes, mainly revealed with computed
tomography (CT), regarding lymph nodes with a diameter of more
than 1cm as pathologic. Although these criteria are generally
accepted, it is known that on the one hand lymph nodes that are
smaller than 1cm may already have undergone malignant
transformation and on the other hand, benign lymphadenopathy
may also lead to enlarged lymph nodes (Castellino et al, 1984).
Focal bone marrow involvement is typical in HL. It may be missed
even if a bilateral bone marrow biopsy is taken in the dorsal iliac
crest (sampling error) (Brunning et al, 1975).
As a noninvasive functional method,
18F-fluorodeoxyglucose
(
18F-FDG-PET) offers tomographic imaging and quantification of
the metabolic activity of tumour tissue with a high spatial
resolution. Supplementing the standard investigations,
18F-FDG-
PET may provide further diagnostic information for staging.
Today, the high sensitivity and specificity of PET for staging is no
longer disputed (Kostakoglu and Goldsmith, 2000; O’Doherty et al,
2002; Schiepers et al, 2003; Staak et al, 2003).
18F-fluorodeoxy-
glucose is the most frequently used PET tracer in the investigation
of malignant lymphoma (Hustinx et al, 2003). The majority of
published studies addressed the staging of lymphoma; only limited
data on the impact of FDG-PET on the treatment planning are
available.
The aim of this prospective study was to assess the clinical
impact of
18F-FDG-PET on the therapeutic management in a larger
patient group than has been published up to now.
MATERIALS AND METHODS
Patients
Between April 1997 and April 2002, 88 consecutive patients with
primary (n¼77) or recurrent (n¼11) HL were enrolled in our
prospective study at the Department of Medicine I, University
of Dresden, and the Department of Haematology/Oncology,
Chemnitz Medical Center, Germany. The disease was verified
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lhistologically in all patients using the World Health Organization
(WHO) classification system (Harris et al, 1999). Patients were
examined with both conventional staging procedures and PET
imaging within 4 weeks before the initiation of therapy. The local
ethics committee approved the study. All patients gave their
written informed consent for the performance of PET, which was
regarded as a routine procedure in staging. The patients
characteristics are presented in Table 1.
Conventional staging procedures
The routine staging comprised physical examination, chest X-ray,
ultrasound, contrast-enhanced CT of the neck, chest, abdomen and
pelvis. Full laboratory work-up included erythrocyte sedimenta-
tion rate (ESR) as well as posterior iliac crest biopsy for bone
marrow evaluation. Magnetic resonance tomography (MRI) or
bone scan was performed additionally in individual patients or
when there was suspicion of osseous involvement. Nodal involve-
ment was defined as lymph node enlargement of 1cm or more on
the basis of clinical or imaging findings. The clinical stage of the
patients was assessed according to the Ann Arbor classification
(Carbone et al, 1971).
18F-FDG-PET imaging
18F-fluorodeoxyglucose positron emission tomography was per-
formed from the proximal femur to the base of the skull and,
depending on the involved locations, also on the head and lower
extremities. The patients fasted for at least 6h before the PET scan.
At 45–60min after injection of 300–370MBq
18FDG, the
investigation was carried out with an ECAT EXACT-HRþ scanner
(Siemens/CTI, TN, USA) with an axial field of view of 15.5cm. The
spatial resolution was 4.0mm (axial) and 4.2mm (transaxial). Six
bed positions were taken for 8min each. A transmission scan for
attenuation correction was obtained for each patient using rotating
68Ga/
68Ge rod sources. Coronal, sagittal and transverse data sets
were reconstructed. The findings were interpreted visually after
examining the section in the black and white mode on a high
resolution display by at least two experienced investigators in
consensus. Pathologically raised FDG uptake was analysed
quantitatively using regions of interest (ROIs) and by determina-
tion of the standardised uptake values (SUVs) (Strauss and Conti,
1991). Regions of interest were marked with isocontours around
a suspicious lesion, setting the lower threshold at the level of
SUV 2.0.
Treatment protocols
Patients with primary diagnosis were assigned to an early,
intermediate and advanced stage according to the current risk
factors of the German Hodgkin’s Lymphoma Study Group, GHSG
(Sieber et al, 2000). This risk stratification may entail a change in
therapy despite identical stage due to the presence of an additional
risk factor (Table 2). Between April 1997 and April 2000, the
patients were enrolled in the protocols of the GHSG. In the limited
stage, the patients received either extended field (EF) irradiation
alone or ABVD plus EF irradiation (trial HD 7 of the GHSG). In the
intermediate stage, the patients were treated with two cycles of
COPP-ABVD with EF or involved field (IF) irradiation (trial HD 8).
In the advanced stage, the patients obtained COPP–ABVD or the
BEACOPP regime (trial HD 9). Between May 2000 and April 2002,
patients were treated in pilot studies using identical inclusion
criteria. In the limited or intermediate stage, the patients received
four or six cycles of ABVD, respectively, plus IF irradiation in case
of residual mass (more than 1.5cm in CT). In the advanced stage,
the patients were treated with the etoposide-free BACOPP-D
regimen, which included cyclophosphamide, adriamycin, dacarba-
zine, procarbazine, prednisolone, bleomycin and vincristine
(Naumann et al, 2002b). In cases of recurrence in patients with
stage I or II disease, the question of the feasibility of curative
Table 1 Patient characteristics (n¼88)
Patients
Characteristic No. %
Sex
Male 57 65
Female 31 35
Age (years)
Median 34 years
Range 17 to 83 years
Disease status
Initial diagnosis 77 87
Recurrent disease 11 13
Histology (WHO classification)
Classical HL
Nodular sclerosis HL 52 59
Lymphocyte-rich classical HL 1 1
Mixed cellularity HL 29 33
Lymphocyte depletion HL 1 1
Hodgkin’s but unclassified 3 3
Nodular lymphocyte-predominant HL 2 2
Clinical stage (conventional staging procedures)
I/IE 7/1 8 9
II/IIE 33/3 36 41
III/IIIE 22/6 28 32
IV 16 16 18
HL¼Hodgikn’s lymphoma.
Table 2 Treatment protocols for patients with primary diagnosis (n¼77)
Hodgkin’s lymphoma
Ann Arbor clinical stage
Risk factors IA, IB, IIA IIB III, IV
KNo risk factor Treatment for limited stages
KThree or more lymph node areas involved Treatment for intermediate stages Treatment for advanced disease
KESR 450mm/h (without B symptoms) or ESR 430mm/h
(with B symptoms)
KLarge mediastinal adenopathy*
a
KExtranodal disease
ESR¼erythrocyte sedimentation rate.
aMediastinal mass greater than one-third of the maximum intrathoracic diameter determined by chest X-ray.
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as well as in the stages III and IV, salvage chemotherapy and if
necessary high-dose chemotherapy with stem cell support was
administered.
Standard of reference
As pathologic confirmation of all lesions (gold standard) was
impossible, the results of all methods performed were subsumed in
a standard of reference. Positive findings at clinical examination,
CT or another conventional technique and appropriate
18F-FDG-
PET findings were interpreted as a manifestation of HL (true-
positive). Negative findings with both standard methods and
18F-
FDG-PET were regarded as true-negative. The result of the
comparison between conventional diagnostics and
18F-FDG-PET
was rated as concordant if both procedures led to an identical
clinical stage. In cases of discrepancy, imaging studies were
reviewed by an interdisciplinary panel comprising of colleagues
from the departments of nuclear medicine, diagnostic radiology
and haematology. In these patients, PET imaging findings within
final staging as well as response to therapy and follow-up
information were used to evaluate the precision of the initial
PET scans.
RESULTS
All patients could be assessed for evaluation.
Concordant results
Using all the methods performed as the standard of reference,
staging by
18F-FDG-PET was concordant with conventional staging
procedures in 70 out of 88 patients (80%). Of these 70 patients, six
had stage I, 29 had stage II, 20 had stage III and 15 had stage IV
according to the Ann Arbor classification.
Discordant results
In 18 patients (20%), discordant results between PET and
conventional staging procedures were found.
True-positive PET findings: In 11 patients (13%), additional
lymphoma sites were found.
True-negative PET findings: In one patient, a false-positive cervical
ultrasound finding was correctly identified by PET.
False-negative PET findings: In three patients,
18F-FDG-PET could
not identify retroperitoneal nodal involvement. In one patient,
18F-
FDG-PET did not detect biopsy-proven liver involvement.
18F-
FDG-PET failed to detect inguinal and cervical nodal HL in two
more cases. Response to therapy and final CT scans were used to
verify the described false-negative nodal PET findings in retro-
spect.
False-positive PET findings: No false-positive PET findings
occurred.
Change in clinical stage
Of the 88 patients examined, the staging would have changed in 18
patients (20%) as a result of the
18F-FDG-PET scan. In all, 11
patients (13%) would have been upstaged and seven patients (8%)
would have been downstaged. There would have been one
upstaging from clinical stage I to II, one from I to IV, four from
II to III, one from II to IV and four from III to IV. Figure 1 shows
the PET image of one patient, where the additional focal liver
uptake would have changed the stage from II to IIIE according to
the modified Ann Arbor classification (patient no. 13). Down-
staging was suggested for two patients from II to I, one patient
from III to I, three patients from III to II and one patient from IV
to II.
Change in treatment strategy
The treatment strategy would have been identical in 72 of 88
patients (82%). As a result of change of stage and risk factors
(Table 2), the treatment strategy would have been changed in 16 of
88 patients (18%). In a total of nine of the 88 patients (10%),
treatment would have been intensified: as a result of upstaging in
six patients and due to an additional risk factor (three or
more lymph node locations involved) in the other three patients.
Three of the 11 patients with recurrent disease would have been
upstaged with consecutive high-dose chemotherapy with auto-
logous stem cell transplantation. The evaluation of the 44 patients
in stage I and II after conventional staging would have resulted in
intensification of therapy in nine patients (nine out of 44, 20%).
Focusing on the 36 patients with stage II disease,
18F-FDG-PET
would have led to intensification of treatment in more than one-
fifth of the patients (eight out of 36, 22%). One patient (1%), who
would have been downstaged, would have received reduced
therapy within the scope of the treatment group comprising
patients with limited stages. The further six patients with false-
negative results would have been downstaged with the conse-
quence of treatment minimization.
In six patients,
18F-FDG-PET findings would have resulted in
upstaging to a stage IV. In two patients, disseminated osseous
involvement (patient no. 2) or bone marrow involvement (patient
no. 14) with consequences for therapy were diagnosed using
supplementary
18F-FDG-PET. The upstaging from stage III to stage
IV would not have translated into changes in treatment strategy in
four patients, including one patient with liver involvement (patient
no. 4), one patient with osseous involvement (patient no. 21) and
two patients with liver and osseous involvement (patient no. 16,
20). Infiltration of the bone marrow was diagnosed in three
patients. In two patients, concordant results were obtained from
bone marrow biopsy and
18F-FDG-PET. As mentioned above, in
one woman (patient no. 14) bone marrow involvement that would
have affected the treatment strategy was detected only by PET. A
focally raised FDG uptake could be detected at multiple locations
in this patient (Figure 2) that could no longer be demonstrated at
post-treatment follow-up. Table 3 shows the 22 patients with
Figure 1 Additional focal liver uptake (solid arrow) would have changed
former stage II (cervical and mediastinal involvement, dashed arrows) to
stage IIIE (patient no. 13, Table 3).
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dures and
18F-FDG-PET.
DISCUSSION
Precise staging is prerequisite to establish the optimum treatment
strategy in patients with HL (Lister et al, 1989). Owing to the
increasing use of combination chemotherapy at early stages, the
result of the H6-F study of the EORTC, use of prognostic factors
and improved CT and MRI techniques, staging laparotomy has
disappeared as a routine staging procedure (Glatstein et al, 1969;
Carde et al, 1993).
In the last few years, the value of FDG-PET for the staging of
malignant diseases has been recognised. The use of elevated
18F-FDG uptake as an indicator for malignant disease renders
18F-FDG-PET independent of morphological conditions. The
published sensitivity and specifity emphasises the value of
18F-
FDG-PET in the staging of lymphoma and explains the increasing
acceptance of this method (Jerusalem et al, 2001; Naumann et al,
2001; Spaepen et al, 2001; Kostakoglu et al, 2002; Guay et al, 2003).
Elstrom et al were able to confirm the high sensitivity of
18F-FDG-
PET for HL, diffuse large-cell NHL, and for the follicular subtype of
indolent NHL (Elstrom et al, 2003).
A review of the literature only revealed a small number of
studies concentrating solely on primary and recurrence staging in
Figure 2 Besides the known infraclavicular and mediastinal uptake (dashed arrow), the multifocal bone marrow uptake (solid arrows) was only detected
by FDG-PET (patient no. 14, Table 3).
Table 3 Patients with suggested changes to stage and/or treatment strategy due to
18F-FDG-PET
Stage
Patient no. Disease status (P, R) Standard PET Change in stage Change in treatment
1 P IIIA IIA Downstaging Minimisation
2 R IAE IVA Upstaging Intensification
3 P IIIB IIB Downstaging No change
4 P IIIA IVA Upstaging No change
5 R IIAE IIIAE Upstaging Intensification
6 R IIB IIIB Upstaging Intensification
7 P IVA IIA Downstaging Minimisation
8 P IIIA IA Downstaging Minimisation
9 P IIA IIIA Upstaging Intensification
10 P IIIAE IIAE Downstaging Minimisation
11 P IIA IIAE No change Intensification
12 P IIB IB Downstaging Minimisation
13 P IIA IIIAE Upstaging Intensification
14 P IIA IVA Upstaging Intensification
15 P IA IIA Upstaging No change
16 P IIIB IVB Upstaging No change
17 P IIA IIA No change Intensification
18 P IIA IIA No change Minimisation
19 P IIA IA Downstaging Minimisation
20 P IIIB IVB Upstaging No change
21 P IIIB IVB Upstaging No change
22 P IIA IIAE No change Intensification
P¼primary diagnosis, R¼recurrent disease.
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lHL. Numerous studies were retrospective, being based on different
lymphoma classifications and investigating ‘malignant lympho-
mas’ without specific analyses of HL and the heterogeneous group
of NHL. Earlier reports referred above all to the excellent precision
of
18F-FDG-PET. It led to upstaging or downstaging with a high
sensitivity and specificity in 10–20% of patients. However, only a
slight effect on the choice of treatment was stated. Our own data
obtained in quite a large number of patients unequivocally
documented the therapeutic relevance of
18F-FDG-PET for patients
with HL.
The prospective study of Bangerter et al (1998) entailed a change
in treatment in six of 44 patients (14%). Jerusalem et al (2001)
investigated 33 patients with HL. Upstaging was indicated in three
patients (9%) and downstaging in four patients (12%). However,
this did not translate into changes in treatment strategy (Jerusalem
et al, 2001). In the study of Hueltenschmidt et al (2001) there was a
change in treatment in two cases (8%), one of which entailed
intensification and one a minimisation of treatment. In the
prospective study of Menzel and colleagues, a correct change in
stages resulted in six out of 28 (21%) patients (Menzel et al, 2002).
Weihrauch et al (2002) reported on upstaging in four patients out
of a total of 22 patients investigated (18%). Of these, one patient
underwent consequent intensification of treatment in accordance
with the therapy strategies of the GHSG (Weihrauch et al, 2002).
The rate of upstaged patients in our study (13%) was quite similar.
To our knowledge, our study comprising 88 prospectively
investigated HL patients is the largest-scale PET study on this topic
that has been published up to now. The main result of our study
was the high rate of treatment intensification in patients with
limited stages I and II (20%). The selective consideration of
patients with stage II increased the rate to 22%.
False-negative PET findings in the detection of CT-positive and
PET-negative areas underscore our own observation and our
recommendation to use
18F-FDG-PET not instead, but in
combination with conventional diagnostics. In six patients (7%)
of our study, the evaluation using the standard of reference
prevented a downstaging owing to false-negative PET findings. In a
further female patient, the
18F-FDG-PET did not detect a third and
thus therapy-relevant lymph node location. Theoretically, in a total
of six patients (7%) this would have erroneously led to a
minimisation of therapy. Weihrauch et al (2002) reported a
similar experience in their prospective study mentioned above, in
which
18F-FDG-PET missed Hodgkin’s foci in six patients (27%).
Although inflammatory lesions, in particular, can cause a pitfall in
PET imaging, we did not observe any false-positive PET findings
that suggested erroneous upstaging in our study (Moog et al,
1998a; Hueltenschmidt et al, 2001; Naumann et al, 2002a).
In our study,
18F-FDG-PET suggested upstaging into a clinical
stage IV in six cases, in two patients with consequences for
treatment owing to the detection of disseminated bone involve-
ment and bone marrow infiltration (BMI). In fact,
18F-FDG-PET is
more sensitive and specific than bone scintigraphy in identifying
cortical bone involvement in malignant lymphoma and is
consequently likely to supersede this method (Moog et al, 1999).
18F-fluorodeoxyglucose positron emission tomography as a
sensitive method for the detection of bone marrow infiltration
can provide additional information to that of bone marrow biopsy
in the staging of malignant lymphomas (Bangerter et al, 1998; Carr
et al, 1998; Moog et al, 1998b; Naumann and Beuthien-Baumann,
in press).
On the basis of our results, we consider
18F-FDG-PET to be of
value especially in stages I and II, since in these stage groups the
input from the PET result on the treatment was substantial. In
stages III and IV,
18F-FDG-PET may not be cost effective. As in
most other publications, our investigation was a monocentric
study. In the future, multicentric studies are absolutely necessary
in order to underpin further the role of
18F-FDG-PET as an
additional method in clinical staging of patients with HL.
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